Outlook Wealth Advisors LLC Invests $295,000 in Medtronic PLC (MDT)
Outlook Wealth Advisors LLC purchased a new stake in shares of Medtronic PLC (NYSE:MDT) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,238 shares of the medical technology company’s stock, valued at approximately $295,000.
A number of other hedge funds also recently bought and sold shares of MDT. Vanguard Group Inc lifted its holdings in shares of Medtronic by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 109,447,687 shares of the medical technology company’s stock valued at $10,766,369,000 after acquiring an additional 1,199,118 shares during the last quarter. First American Bank lifted its holdings in shares of Medtronic by 1.8% in the 4th quarter. First American Bank now owns 56,814 shares of the medical technology company’s stock valued at $5,167,000 after acquiring an additional 1,001 shares during the last quarter. Valicenti Advisory Services Inc. lifted its holdings in shares of Medtronic by 0.4% in the 4th quarter. Valicenti Advisory Services Inc. now owns 69,543 shares of the medical technology company’s stock valued at $6,326,000 after acquiring an additional 305 shares during the last quarter. Consolidated Investment Group LLC lifted its holdings in shares of Medtronic by 45.5% in the 4th quarter. Consolidated Investment Group LLC now owns 41,600 shares of the medical technology company’s stock valued at $3,784,000 after acquiring an additional 13,000 shares during the last quarter. Finally, Eukles Asset Management bought a new position in shares of Medtronic in the 4th quarter valued at about $1,708,000. 81.23% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently commented on MDT. Zacks Investment Research raised shares of Medtronic from a “sell” rating to a “hold” rating in a report on Monday. Northland Securities reaffirmed a “hold” rating and issued a $84.00 price target on shares of Medtronic in a report on Monday, March 18th. Barclays reaffirmed a “buy” rating and issued a $104.00 price target on shares of Medtronic in a report on Wednesday, February 20th. Wells Fargo & Co lowered their price target on shares of Medtronic from $101.00 to $100.00 and set a “market perform” rating for the company in a report on Thursday, April 4th. Finally, Citigroup increased their price target on shares of Medtronic from $95.00 to $101.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Ten investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $103.39.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 19th. The medical technology company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.05. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 16.10% and a return on equity of 13.85%. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.17 EPS. Sell-side analysts expect that Medtronic PLC will post 5.15 EPS for the current fiscal year.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Featured Article: What is insider trading?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.